Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study.
1/5 보강
: The rs61764370 T>G single-nucleotide polymorphism (SNP), located in a let-7 microRNA binding site within the 3' untranslated region (3'UTR) of the gene, may modulate tumor aggressiveness by alteri
- 표본수 (n) 64
APA
Berisha TC, Cucu MG, et al. (2026). Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study.. Biomedicines, 14(2). https://doi.org/10.3390/biomedicines14020319
MLA
Berisha TC, et al.. "Adverse Histopathological Features in Colorectal Cancer Associated with KRAS rs61764370 SNP: A Preliminary Study.." Biomedicines, vol. 14, no. 2, 2026.
PMID
41751217 ↗
Abstract 한글 요약
: The rs61764370 T>G single-nucleotide polymorphism (SNP), located in a let-7 microRNA binding site within the 3' untranslated region (3'UTR) of the gene, may modulate tumor aggressiveness by altering post-transcriptional gene regulation. This study evaluated its association with adverse histopathological features in colorectal cancer (CRC). : A preliminary study on 83 CRC patients carrying either the TT (wild-type, n = 64) or TG (heterozygous, n = 19) genotype was analyzed. Clinicopathological variables included patient sex, tumor location, American Joint Committee on Cancer (AJCC) staging system, histological grade, perineural invasion (PNI), and lymphovascular invasion (LVI). A composite "tumor aggressiveness" score was defined based on the presence of Grade 3 differentiation, LVI, and/or PNI. Group comparisons were performed using the Chi-square test or Fisher's exact test, as appropriate. : No statistically significant differences were observed in sex ( = 0.689), tumor location ( = 0.781), or stage at diagnosis ( = 0.812). Poorly differentiated tumors (Grade 3) were present in 20.3% of TT patients and absent in TG carriers ( = 0.06), while low-grade tumors (Grade 1) were more prevalent among TG patients (47.4%) compared to TT (29.7%). The composite high-aggressiveness score was lower in TG (36.8%) than in TT (48.4%), while co-occurrence of PNI and LVI was similar in both groups (~26%). : Although no significant associations were identified, TG carriers showed a tendency toward lower-grade, less aggressive tumors. Given the limited sample size, these findings should be interpreted with caution, necessitating larger cohorts in order to validate results.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- NG25 Enhances Anti-Tumor Immunity in -Mutant Colorectal Cancer.
- Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.
- Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line.
- Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.
- MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET Inhibition.